Lisa Licitra

40.6k total citations · 9 hit papers
447 papers, 16.0k citations indexed

About

Lisa Licitra is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lisa Licitra has authored 447 papers receiving a total of 16.0k indexed citations (citations by other indexed papers that have themselves been cited), including 243 papers in Otorhinolaryngology, 238 papers in Oncology and 161 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lisa Licitra's work include Head and Neck Cancer Studies (239 papers), Lung Cancer Treatments and Mutations (105 papers) and Cancer Immunotherapy and Biomarkers (70 papers). Lisa Licitra is often cited by papers focused on Head and Neck Cancer Studies (239 papers), Lung Cancer Treatments and Mutations (105 papers) and Cancer Immunotherapy and Biomarkers (70 papers). Lisa Licitra collaborates with scholars based in Italy, United States and France. Lisa Licitra's co-authors include Laura D. Locati, Paolo Bossi, Vincent Grégoire, Enriqueta Felip, J Lefebvre, Gemma Gatta, Ezra E.W. Cohen, Cristiana Bergamini, Federica Perrone and Marco Guzzo and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lisa Licitra

424 papers receiving 15.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib in Progressive Medullary Thyroid Cancer

2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →
High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma

2006 507 citations Lisa Licitra, Federica Perrone et al. Journal of Clinical Oncology profile →
Rare cancers are not so rare: The rare cancer burden in Europe

2011 500 citations Lisa Licitra et al. European Journal of Cancer profile →
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

2019 491 citations Ezra E.W. Cohen, Barbara Burtness et al. profile →
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 477 citations Lisa Licitra et al. profile →
Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010 456 citations Lisa Licitra et al. profile →
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

2013 314 citations Lisa Licitra, Makoto Tahara et al. profile →
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2020 240 citations Paolo Bossi, Lisa Licitra et al. profile →
Management of Salivary Gland Malignancy: ASCO Guideline

2021 206 citations J.L. Geiger, Nofisat Ismaila et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Lisa Licitra

Since Specialization

Citations

This map shows the geographic impact of Lisa Licitra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Licitra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Licitra more than expected).

Fields of papers citing papers by Lisa Licitra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Licitra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Licitra. The network helps show where Lisa Licitra may publish in the future.

Co-authorship network of co-authors of Lisa Licitra

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Licitra. A scholar is included among the top collaborators of Lisa Licitra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Licitra. Lisa Licitra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma 2025 ·Cancers ·(unknown), (unknown), Marta Lucchetta, Stefano Cavalieri, Ruud H. Brakenhoff, (unknown), Kathrin Scheckenbach, Tito Poli, Lisa Licitra, (unknown)	2
2	Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study 2025 ·European Journal of Cancer ·Salvatore Alfieri, (unknown), Sara Marceglia, (unknown), (unknown), (unknown), (unknown), (unknown), Stefano Cavalieri, Cristiana Bergamini, Elena Colombo, (unknown), Loris De Cecco, (unknown), Nicola Alessandro Iacovelli, Marco Guzzo, Ester Orlandi, Laura D. Locati, Paolo Bossi, Lisa Licitra, Francesca Taverna	0
3	Charged particle radiotherapy for thyroid cancer. A systematic review 2024 ·Critical Reviews in Oncology/Hematology ·Lucia Pia Ciccone, (unknown), Maria Bonora, Sara Ronchi, (unknown), (unknown), Angelica Facoetti, (unknown), Giuseppe Magro, Barbara Vischioni, Laura D. Locati, Lisa Licitra, W. Sauerwein, Ester Orlandi	0
4	Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck 2024 ·Cancer Treatment Reviews ·Ben O’Leary, Heath D. Skinner, Jonathan D. Schoenfeld, Lisa Licitra, Christophe Le Tourneau, Christina Esdar, Andreas Schröeder, (unknown), Amanda Psyrri	7
5	Developing a trial design to establish BNCT as clinical application: insight for the national italian center for oncological hadrontherapy (CNAO) 2024 ·Health and Technology ·Lisa Licitra, Stefano Cavalieri, Carmine Tinelli, (unknown), Ester Orlandi	0
6	Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience 2023 ·Oral Oncology ·Stefano Cavalieri, Francesca Platini, Francesco Barretta, (unknown), (unknown), Cristiana Bergamini, Carlo Resteghini, Elena Colombo, Nicola Alessandro Iacovelli, Marzia Franceschini, Giuseppina Calareso, (unknown), (unknown), (unknown), Luisa Toffolatti, Mauro Guglielmo, Carla Ripamonti, Laura Cosmai, Lisa Licitra, Salvatore Alfieri	4
7	106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study 2023 ·Immuno-Oncology Technology ·Richard Greil, Barbara Burtness, Simon Laban, Irene Braña, (unknown), Thorsten Fuereder, Åse Bratland, Lisa Licitra, Tamara Rordorf, Amanda Psyrri, Aron Popovtzer, Brett Hughes, Makoto Tahara, J. Lin, (unknown), (unknown), Kevin J. Harrington	1
8	Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111) 2023 ·Clinical Cancer Research ·(unknown), Axelle Loriot, Nicolas D. Huyghe, Rose‐Marie Goebbels, Antonella Mendola, Anne-Sophie Govaerts, Catherine Fortpied, Paméla Baldin, Lisa Licitra, Yassine Lalami, Paul M. Clément, Jean‐Pascal Machiels, Sandra Schmitz	0
9	Management of patients with skin adnexal carcinomas 2023 ·SHILAP Revista de lepidopterología ·Stefano Cavalieri, Cristiana Bergamini, Salvatore Alfieri, Carlo Resteghini, (unknown), Elena Colombo, (unknown), Lisa Licitra	2
10	Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma 2021 ·Radiotherapy and Oncology ·Stefano Cavalieri, Sara Ronchi, Amelia Barcellini, Maria Bonora, Barbara Vischioni, Viviana Vitolo, (unknown), Michele Del Vecchio, Lisa Licitra, Ester Orlandi	14
11	Management of Salivary Gland Malignancy: ASCO Guideline breakdown → 2021 ·Journal of Clinical Oncology ·J.L. Geiger, Nofisat Ismaila, Beth M. Beadle, Jimmy J. Caudell, Nicole G. Chau, Daniel G. Deschler, Christine M. Glastonbury, (unknown), Eric Lamarre, Harold Lau, Lisa Licitra, Michael G. Moore, Cristina P. Rodriguez, Anna Roshal, Raja R. Seethala, Paul Swiecicki, Patrick K. Ha	206
12	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer 2020 ·Modern Pathology ·Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, (unknown), Ezra E.W. Cohen, Kevin J. Harrington, Denis Soulières, Christophe Le Tourneau, Lisa Licitra, Barbara Burtness, Ramona F. Swaby	71
13	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions 2020 ·Cells ·(unknown), (unknown), Elisa Roca, Alberto Paderno, Davide Mattavelli, Chiara Romani, Pierre Saintigny, Senada Koljenović, Lisa Licitra, Loris De Cecco, Paolo Bossi	11
14	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use 2019 ·Clinical Cancer Research ·Robert L. Ferris, Lisa Licitra, Jérôme Fayette, Caroline Even, George R. Blumenschein, Kevin J. Harrington, J. Guigay, Everett E. Vokes, Nabil F. Saba, Robert I. Haddad, S. Ramkumar, Jeffery S. Russell, Peter Brossart, Makoto Tahara, A. Dimitrios Colevas, Fernando Concha‐Benavente, Mark Lynch, Li Li, Maura L. Gillison	115
15	Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1 2018 ·Clinical Cancer Research ·Denis Soulières, Lisa Licitra, Ricard Mesı́a, Éva Remenár, Shau-Hsuan Li, А. А. Карпенко, Marie Chol, Ying A. Wang, Nadia Solovieff, (unknown), Dalila Sellami, Sandrine Faivre	34
16	Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC) 2017 ·European Journal of Cancer ·Christine de Balincourt, Denis Lacombe, Corneel Coens, Marcel den Dulk, Jean‐Pascal Machiels, Damien C. Weber, Martin Spahn, Roberto Salgado, Bernd Kasper, Peter Hau, Lisa Licitra, Fay Betsou, Kozo Kataoka, Carmela Caballero, Yan Liu, Coen Hurkmans, Serge Évrard	13
17	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab 2016 ·Clinical Cancer Research ·Paolo Bossi, Cristiana Bergamini, Marco Siano, Maria Cossu Rocca, (unknown), (unknown), (unknown), Edoardo Marchesi, Barbara Cortelazzi, Federica Perrone, Silvana Pilotti, Laura D. Locati, Lisa Licitra, Silvana Canevari, Loris De Cecco	53
18	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer 2015 ·Clinical Cancer Research ·Martin Schlumberger, Barbara Jarząb, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith C. McCaffrey, Kate Newbold, Roger Allison, Renato Martins, Lisa Licitra, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn A. Burmeister, Yasuhiro Funahashi, Min Ren, James P. O'Brien, Steven I. Sherman	184
19	Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications 2014 ·Clinical Cancer Research ·Yoshitsugu Mitani, Pulivarthi H. Rao, Sankar N. Maity, Yu-Chen Lee, Renata Ferrarotto, (unknown), Lisa Licitra, Scott M. Lippman, Merrill S. Kies, Randal S. Weber, Carlos Caulı́n, Sue-Hwa Lin, Adel K. El‐Naggar	56
20	Cabozantinib in Progressive Medullary Thyroid Cancer breakdown → 2013 ·Journal of Clinical Oncology ·Rossella Elisei, Martin Schlumberger, Stefan Müller, Patrick Schöffski, Marcia S. Brose, Manisha H. Shah, Lisa Licitra, Barbara Jarząb, В. С. Медведев, Michael C. Kreißl, Bruno Niederle, Ezra E.W. Cohen, Lori J. Wirth, Haythem Ali, Colin Hessel, Yifah Yaron, Douglas W. Ball, Barry D. Nelkin, Steven I. Sherman	850

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact